A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumoursGabriel Mak, Hendrik‐Tobias Arkenau, Kurt R. Auger et al.|British Journal of Cancer|2019Cited by 103
Risk of Ovarian Cancer Relapse ScoreIvana Rizzuto, Sarah P. Blagden, Chara Stavraka et al.|International Journal of Gynecological Cancer|2015Cited by 52
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I studySarah P. Blagden, Essam Ghazaly, Ivana Rizzuto et al.|British Journal of Cancer|2018Cited by 43
Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.Sarah P. Blagden, Christopher McGuigan, Ivana Rizzuto et al.|Journal of Clinical Oncology|2015Cited by 7
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.Hendrik‐Tobias Arkenau, Li Yan, Anas Gazzah et al.|Journal of Clinical Oncology|2015Cited by 7